Compare Cronos Group Inc (CRON) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Paychex, Inc. — how do they compare? Cronos Group Inc trades at $3.08 (market cap $1.11B), while Paychex, Inc. trades at $121.14 (market cap $43.10B). The key difference: Paychex, Inc. is far larger — about 38.8× Cronos Group Inc's market cap, and Paychex, Inc. pays a 3.93% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| CRON | PAYX | |
|---|---|---|
Market Cap | $1.11B | $43.10B |
Sector | Health | Industrials |
52-Week High | $3.27 | $140.81 |
52-Week Low | $2.30 | $85.57 |
Enterprise Value | $310.67M | $46.59B |
Dividend Yield | — | 3.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.10 with a 0.98% daily gain, showing bullish technical momentum. The company delivered strong Q2 2026 results with 58% YoY revenue growth and earnings beat, while maintaining #1 market share in Canadian vapes and edibles. Despite negative net income in 2025, revenue growth accelerated to $147M with improving margins. Technical indicators show bullish moving averages but RSI suggests potential overbought conditions near $3 resistance.
Outlook remains positive with international expansion and European cannabis legalization driving growth, though competitive pressures and execution risks persist. Analyst consensus is mixed with 60% hold ratings, reflecting cautious optimism about CRON's turnaround trajectory from previous losses to projected 39% profit margin by 2026.
Paychex (PAYX) trades at $120.04, down slightly by 0.07% on the day, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.32 exceeding the $1.31 estimate. Revenue grew to $5.57 billion in 2025, though net income margin dipped to 27.03%. Recent news highlights expansion of its WISE platform and steady small business employment trends, supporting growth prospects.
The outlook remains positive given consistent earnings outperformance and strategic initiatives, but risks include elevated valuation ratios and potential economic sensitivity. Analyst consensus is mixed with a hold-heavy rating, and the current price sits above the $114.50 target, suggesting limited near-term upside. Dividend payments provide income support, yet investors should weigh growth against premium multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
